💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Linagliptin

CHEMBL237500 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
472.5 g/mol
LogP
1.9
Phase
4

A DPP-4 inhibitor used to treat type 2 diabetes, and studied for its potential cardiovascular and kidney protective effects. It works by preventing the breakdown of incretin hormones that stimulate insulin secretion after meals.

Molekularmasse

472,5000 g/mol

LogP

1,90

TPSA

113,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Cardiovascular Disease Osteoporosis Schizophrenia Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Heart Failure

Wirkmechanismus

Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C

                

                

                
                

                    
InChI

                    
InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H28N8O2

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
Rotierbare Bindungen

                        
4

                    

                    
                    
                    

                        
Schwere Atome

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A DPP-4 inhibitor used to treat type 2 diabetes, and studied for its potential cardiovascular and kidney protective effects. It works by preventing the breakdown of incretin hormones that stimulate insulin secretion after meals.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Linagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL237500.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10096344.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.